Trial Profile

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Betrixaban (Primary) ; Enoxaparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms APEX
Sponsors Portola Pharmaceuticals

01 Feb 2023 Results assessing the Age-D-dimer-Albumin score for predicting thrombosis in a non-COVID-19 medically ill population from the APEX trial, published in the Journal of Thrombosis and Thrombolysis.
01 Mar 2022 Results published in the Thrombosis Research
08 Aug 2019 Results published in the Journal of Thrombosis and Haemostasis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com